- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| APREA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Aprea Therapeutics GAAP EPS of -$0.66 | 1 | Seeking Alpha | ||
| 14.05. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update | 82 | GlobeNewswire (Europe) | ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial ... ► Artikel lesen | |
| 14.05. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | Aprea Therapeutics GAAP EPS of -$0.49 beats by $0.20, revenue of $0.21M beats by $0.06M | 1 | Seeking Alpha | ||
| 25.03. | Aprea Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | Aprea Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 160 | GlobeNewswire (Europe) | ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119... ► Artikel lesen | |
| 12.03. | Aprea and MD Anderson sign agreement for APR-1051 | 1 | Pharmaceutical Business Review | ||
| 11.03. | Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) | 158 | GlobeNewswire (Europe) | DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen | |
| 05.02. | Aprea Therapeutics erweitert Patent-Portfolio für Krebsmedikamente | 4 | Investing.com Deutsch | ||
| 05.02. | Aprea Therapeutics expands cancer drug patent portfolio | 3 | Investing.com | ||
| 05.02. | Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics | 1 | GlobeNewswire (USA) | ||
| 05.02. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.01. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.24 | Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward | 214 | GlobeNewswire (Europe) | Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially... ► Artikel lesen | |
| 12.08.24 | Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | 179 | GlobeNewswire (Europe) | Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 - no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash... ► Artikel lesen | |
| 17.06.24 | Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 | 199 | GlobeNewswire (Europe) | APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,170 | +0,36 % | Evotec: Zwischen Hoffen und Bangen | Die Evotec-Aktie macht den Anlegern seit langer Zeit bereits Kummer. Der Aktienkurs gibt ständig nach. Da hilft auch kein Daumendrücken. Bisher zumindest nicht, denn etwas Hoffnung keimt jetzt auf,... ► Artikel lesen | |
| BB BIOTECH | 32,850 | +0,77 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
| CUREVAC | 3,934 | +0,82 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
| VALNEVA | 2,776 | -0,14 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH 03.06.2025 / 14:27 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den... ► Artikel lesen | |
| BIOGEN | 115,80 | +0,17 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
| ILLUMINA | 73,28 | +0,54 % | Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? | ||
| GINKGO BIOWORKS | 6,750 | +2,27 % | Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer | BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| BIONTECH | 99,25 | +1,79 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
| DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen |
Das Unternehmen APREA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APREA THERAPEUTICS INC finden Sie auf Wallstreet Online.